AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM).

SC-919 (SC919) is a potent, selective inhibitor of IP6K (Inositol hexakisphosphate kinase) with IC50 of <5.2, <3.8 and 0.65 nM for human IP6K1/2/3, respectively.

JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type amino acid transporter 1) inhibitor. JPH203 can very potently inhibit l-leucine uptake. JPH203 inhibits YD-38 cell growth. JPH203 up-regulated the population of apoptotic Y

SNX631 (SNX-631) is a potent, selective inhibitor of CDK8/19 Mediator kinase with IC50 of 10.3 nM in the NF κB-dependent cell-based assays.

RMC-6236 (Compound A122) is a potent RAS(ON)MULTI inhibitor and can be used for the research of cancer.

Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.

BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight.

S1PR5-IN-1 (Compound 7a) is a selective and BBB-penetrable S1PR5 inhibitor with an IC50 of 85.4 nM. S1PR5-IN-1 has a superior binding capacity on S1PR5 with Kds of 2.2, 4.6, and 27.6 nM for recombinant human S1PR5 cell membranes, C57BL/6 mouse brain, and human cerebral cortex, respectively. S1PR5-IN-1 can be used for neurodegenerative disorders like multiple sclerosis research.

A broad-spectrum natural antifungal compound that acts as a selective and highly potent fungal Pkc1 kinase inhibitor.

HY041004 is the first small molecule inhibitor of deubiquitinase Josephin Domain-containing protein 2 (JOSD2) with IC50 of 0.26 uM for JOSD2 catalytic activity inhibition.

Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing.

Asimadoline HCl is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline has also been shown to be used in the treatment of irritable bowel syndrome.

SKPer1 (XMU-MP-8) is a small-molecule degrader of SKP2 that triggers degradation of the oncoprotein SKP2 and specifically kills SKP2-expressing cancer cells.

EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity with Ki value of 2.5±0.5 nM.

Sunobinop (S 117957) is a modulator of the opioid receptor-like orphan receptor (ORL1).

Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER+/HER2+ cancer.

CP 94253 hydrochloride is a potent and selective serotonin 5-HT1B receptor agonist, with Ki values to be 2 nM for 5-HT1B and 89, 860, 49 and 1600 nM for 5-HT1A, 5-HT1C, 5-HT1D and 5-HT2 receptors respectively.

Novel PDZ binding kinase (PBK) inhibitor.

The TSCM-Ki Cocktail is a kinase inhibitor combination product validated through high-throughput screening. Its core function is to significantly increase the ratio of T memory stem cell (Tscm)-like cells—possessing self-renewal capacity and high persistence—in the final CAR-T cell product by transiently and reversibly modulating key kinase signaling pathways during the in vitroexpansion phase, thereby effectively preventing terminal T-cell differentiation. CAR-T cells manufactured using this product demonstrate superior tumor clearance capability and long-term immune memory in preclinical models.

TPT-004 is a highly potent, selective tryptophan hydroxylase (TPH) with IC50 of 77 nM and 16 nM for TPH1 and TPH2, respectively.

Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).

NF340 is a potent and selective P2Y11 receptor antagonist. NF340 inhibits the activity of P2Y11R by completely combining with ATP-binding amino acid residues. NF340 ameliorates inflammation in human fibroblast-like synoviocytes and can be used for rheumatoid arthritis research.

Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8.

Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models.

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage.

Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands.

Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC).

Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.